scout

All News

The use of multidrug chemotherapy and bone marrow transplantation in cancer treatment has made the utilization of reliable, long-term venous access (LTVA) an essential component of cancer therapy. The placement of LTVA devices not only permits the delivery of these complex therapeutic regimens but also drastically improves patients’ quality of life.

In clinical studies, formal response criteria have been developed and have gained wide acceptance. The National Cancer Institute (NCI) has proposed and implemented newer standard response criteria called Response Evaluation Criteria in Solid Tumors (RECIST). In contrast, the World Health Organization (WHO) has a different standard for assessing response. Major differences between these guidelines are outlined below.

Myeloproliferative neoplasms are a group of clonal myeloid cell–derived disorders characterized by myeloproliferation without dysplasia, bone marrow hypercellularity, and predisposition to thrombosis, hemorrhage, and bone marrow fibrosis.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a joint effort from the American Cancer Society and IBM that aims to use the cognitive power of Watson to help cancer patients deal with their disease.